Markus Raderer

21PUBLICATIONS

58CO-AUTHORS

Molecular targetsTumour immunologySolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (21)

Sort by Publication Date:

|Jun 02, 2026

B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer.

|Dec 03, 2024

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT-Lymphoma) of the Intestine: A Single Center Analysis.

Oskar Steinbrecher, Barbara Kiesewetter, Werner Dolak

|Jun 24, 2024

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.

E Baudin, J Capdevila, D Hörsch

|Mar 26, 2024

From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.

Philipp Melhorn, Peter Mazal, Ladislaia Wolff

|Jan 12, 2024

Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms.

Philipp Melhorn, Peter Mazal, Ladislaia Wolff

|Jan 11, 2024

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.

Marianne Pavel, Harald Lahner, Dieter Hörsch

Pageof 4

Frequent Collaborators

12 joint publications

Barbara Kiesewetter

Philipp Melhorn

G Rendl

B Sipos

A Becherer

C Trummer

W Hitzl

M Ardelt

H J Gallowitsch

C Pirich

Frequent Collaborators

12 joint publications

Barbara Kiesewetter

4 joint publications

Philipp Melhorn

1 joint publications

G Rendl

1 joint publications

B Sipos